Ocugen, Inc. (OCGN) has a MoatMap StockRank of 12/100 based on Quality (8/100), Value (45/100), and Momentum (42/100) factor scores. The current signal is STRONG SELL. Ocugen is a highly speculative biotechnology firm with a history of pivot strategies and heavy cash burn. It lacks any of the validated, high-utilization manufacturing moats seen in true CDMO leaders, failing our quality and capital allocation criteria.
Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccines for infectious diseases. Its strategic partnerships, particularly for vaccine development, alongside a proprietary modifier gene therapy platform for ocular diseases, offer diversification in a high-risk, high-reward sector. Ocugen is a clinical-stage biotechnology company pursuing both gene therapy solutions for rare eye diseases and broader public health initiatives.
| Price | $1.30 |
| Market Cap | $477M |
| P/E (Forward) | -5.83 |
| Price/Book | -35.13 |
| Return on Equity | -660.0% |
| Return on Invested Capital | -306.1% |
| Debt/Equity | 573.58 |
| Gross Margin | 0.0% |
| Operating Margin | -1163.7% |
| Revenue Growth | 3.5% |
| Free Cash Flow | $-34M |
Ocugen, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).